The Trump administration announced Tuesday it will end a key subsidy program for Medicare Part D, the government's prescription drug benefit, effective at the end of 2027. The move, according to Centers for Medicare and Medicaid Services Administrator Mehmet Oz, is intended to stop benefits from flowing to corporate insurance companies.

Medicare Part D is utilized by tens of millions of older and disabled Americans for their prescription drug needs. The administration's decision to let the subsidies expire is expected to lead to higher prescription costs and increased monthly premiums for approximately half of the program's beneficiaries.

Administration officials indicated that changes would take effect in 2027, with enrollees to be informed of their new monthly costs later this fall. Currently, the government provides billions of dollars annually to insurance companies as subsidies to maintain an average monthly premium of $36 per person for prescription drug coverage, according to KFF, a non-profit health policy organization.

KFF estimates that the discontinuation of these subsidies could raise premiums for some individuals by as much as $20 per month. This decision comes at a time when Affordable Care Act (ACA) subsidies have also expired, and healthcare costs remain a significant concern for voters heading into the midterm elections.

In a post on X, formerly Twitter, Oz stated that the market is being stabilized, rendering the "bailout" unnecessary. He projected that premiums would rise by less than $10 for most Medicare recipients, with many potentially seeing even lower costs. Oz also highlighted continued efforts to lower prescription drug prices through various initiatives, including access to GLP-1 medications for $50 per month.

The Trump administration has been critical of the Biden administration's Inflation Reduction Act, alleging that it primarily benefited major insurance companies and contributed to rising premiums. Biden administration officials, conversely, promoted the Inflation Reduction Act for empowering the government to negotiate prices for certain high-cost medications with drug manufacturers.

The expiration of the ACA subsidies previously lowered out-of-pocket monthly premium costs for individuals purchasing health insurance through the marketplace. The parallel expiration of the Medicare Part D subsidies adds another layer of potential financial pressure on beneficiaries.

Questions remain regarding the exact impact on different groups of Medicare beneficiaries and the specific mechanisms the administration plans to employ to ensure continued access to affordable prescription drugs, especially for those with chronic conditions or high medication needs.